Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 8Recruiting 6Unknown 5Terminated 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 2OTHER_GOV 1

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Gynecologic 1Gastrointestinal 1

Conditions

Recurrence 2Pregnancy Related 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Endometrial Neoplasms 1Burkitt Lymphoma 1

Interventions

Specimen Handling 336Magnetic Resonance Spectroscopy 333Radiotherapy 315Cyclophosphamide 295pembrolizumab 282Cisplatin 266Carboplatin 245Drug Therapy 237Blood Specimen Collection 233Biopsy 206Bevacizumab 187Gemcitabine 177venetoclax 172Radiosurgery 169Capecitabine 165Oxaliplatin 163fludarabine 160Nivolumab 156Paclitaxel 155Standard of Care 137Surveys and Questionnaires 131Surgical Procedures, Operative 130Dexamethasone 127Fluorouracil 125Docetaxel 113tislelizumab 110Rituximab 110Cytarabine 104atezolizumab 101Azacitidine 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × OTHER × Antibodies, Monoclonal × Clear all
NCT06366347 2026-02-11

ALPINE: Maintenance Letrozole/Abemaciclib

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Gynecologic

Endometrial Neoplasms

NCT06550141 2025-11-14

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Massachusetts General Hospital

Phase 2 Recruiting
28 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT07033663 2025-08-15

NEWbornIMMPACT

Fundació Sant Joan de Déu

Recruiting
90 enrolled

Pregnancy Related

NCT07051850 2025-07-15

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Seoul St. Mary's Hospital

Recruiting
174 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT06796517 2025-01-28

Immunotherapy in Lymphoma

Seoul St. Mary's Hospital

Recruiting
72 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell

NCT05462496 2024-10-15

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Icahn School of Medicine at Mount Sinai

Phase 2 Recruiting
25 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡